# TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization

> **NCT02211066** · PHASE4 · COMPLETED · sponsor: **Hospital Clinic of Barcelona** · enrollment: 59 (actual)

## Conditions studied

- Patients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT02211066
- **Lead sponsor:** Hospital Clinic of Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2019-06
- **Final completion:** 2019-06-12
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2019-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211066, "TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02211066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*